Skip to content
RDL
Network
Ecosystem
Switch app
TR
About
FAQ
Sign in
Get started
Potentiating effect of ribavirin on the anti-retrovirus activity of 3′-azido-2,6-diaminopurine-2′,3′-dideoxyriboside in vitro and in vivo — Jan Balzarini (1989) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
Potentiating effect of ribavirin on the anti-retrovirus activity of 3′-azido-2,6-diaminopurine-2′,3′-dideoxyriboside in vitro and in vivo
Shared by
De Clercq Erik
KU Leuven
Potentiating effect of ribavirin on the anti-retrovirus activity of 3′-azido-2,6-diaminopurine-2′,3′-dideoxyriboside in vitro and in vivo
Article
1989
en
Authors
JB
Jan Balzarini
PH
Piet Herdewijn
De Clercq Erik
KU Leuven
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Related publications
Article
1990
Potentiating effect of ribavirin on the in vitro and in vivo antiretrovirus activities of 2',3'-dideoxyinosine and 2',3'-dideoxy-2,6-diaminopurine riboside.
Jan Balzarini
,
Lieve Naesens
,
Robins Mj
,
De Clercq Erik
Article
1989
The antiviral activity of 9-β-D-arabinofuranosyladenine is enhanced by the 2′,3′-dideoxyriboside, the 2′,3′-didehydro-2′,3′-dideoxyriboside and the 3′-azido-2′,3′-dideoxyriboside of 2,6-diaminopurine
Jan Balzarini
,
De Clercq Erik
Article
1988
The in vitro and in vivo anti-retrovirus activity, and intracellular metabolism of 3′-azido-2′,3′-dideoxythymidine and 2′,3′-dideoxycytidine are highly dependent on the cell species
Jan Balzarini
,
Rudi Pauwels
,
Masanori Baba
,
Piet Herdewijn
,
De Clercq Erik
,
Samuel Broder
,
David G. Johns
Article
1993
Activity of the anti-HIV agent 9-(2-phosphonyl-methoxyethyl)-2,6-diaminopurine against cytomegalovirus in vitro and in vivo
Johan Neyts
,
F S Stals
,
C. A. Bruggeman
,
De Clercq Erik
Article
1987
The 2′,3′-dideoxyriboside of 2,6-diaminopurine selectively inhibits human immunodeficiency virus (HIV) replication invitro
Jan Balzarini
,
Rudi Pauwels
,
Masanori Baba
,
Morris J. Robins
,
Ruiming Zou
,
Piet Herdewijn
,
De Clercq Erik
Discussion(0)
No comments yet. Be the first to comment.